(PharmaNewsWire.Com, March 16, 2018 ) The report "Urinary tract Infection (UTI) Market by Type Of Medication (Penicillin & Combinations, Quinolones, Aminoglycoside-Antibodies, Cephalosporin, Sulphonamides, Azoles & Amphotericin B, Tetracycline And Nitrofurans), By Type Of Indication (Uncomplicated UTI, Complicated UTI, Recurring Complicated UTI, And Neurogenic Bladder Infection) - Forecast to 2021", The Urinary tract Infection (UTI) market is expected to reach USD 13.88 Billion by 2021 from an estimated USD 9.71 Billion in 2016, at a CAGR of 3.2%. The key factors are sudden rise in the prevalence rate and the diagnosis for the disease. This has started the opportunities for major players to allocate their resources towards research and development of a combination therapy. With the launch of new drugs for multiple indications under urinary tract infections, and label expansion for drugs which are already existing, the market is expected to boost further.
Browse through 180 Pages and in-depth TOC on "Urinary tract Infection (UTI) Market "
Early buyers will receive 10% customization on reports.
By medication, combination of drugs accounted for the largest share of the market in 2016
On the basis of medication, the Urinary tract Infection (UTI) market has been segmented into Penicillin & Combinations, Quinolones, Aminoglycoside-Antibodies, Cephalosporin, Sulphonamides, Azoles & Amphotericin B, Tetracycline and Nitrofurans. The Penicillin & Combinations segment is divided into Amoxicillin and Amoxicillin-Clavulanate Potassium combination. The Quinolones class includes Ciprofloxacin, Levofloxacin, Norfloxacin and Nalidixic Acid. The Aminoglycoside Antibodies class includes Gentamicin and Amikacin. The Cephalosporin class includes Ceftriaxone, Cefixime, Cefuroxime, and Cephalexin. Sulphonamides mainly of Sulfamethoxazole and Trimethoprim combination is expected to be the fastest-growing segment during the forecast period..
On the basis of type, the Urinary tract Infection (UTI) market has been segmented into into Uncomplicated UTI, Complicated UTI, Recurring Complicated UTI, and Neurogenic Bladder Infection.
Asia Pacific accounted for the largest share of the Urinary tract Infection (UTI) market in 2016, followed by Europe. The large share of the North American Urinary tract Infection (UTI) market can be attributed to the growth rising rate of diagnostics, gradual adoption of improved technologies, emerging health care infrastructures, and increased disposable income lack of knowledge of this transferable diseases and personnel hygiene is prominent in these regions .
The various players in the Urinary tract Infection (UTI) market include Pfizer, Inc., AstraZeneca plc, Johnson & Johnson, Novartis International AG., F. Hoffmann La Roche Ltd., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, and Cipla Ltd., among others.
About MarketDataForecast™
Market Data Forecast is a market research firm offering syndicated research, consults and industry newsletters across various domains & verticals. With a well-established in-house team of experts from diverse fields and outsource research network across 100+ countries, we are the sole research providers for the majority of Fortune 500 companies. Along with the standards of reports being on par excellence, our unique services like free customization, analyst support for the period of six months post to the purchase will be the flag bearers and differentiates us from the rest. Our experience and in-depth understanding of various business environments will be a support to you and your organization in making well-informed decisions.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
